August 01, 2025

Dana-Farber Research News 08.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.

Dana-Farber

July 24, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplan...

The ASCO Post

July 14, 2025

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for pediatric acute myeloid leukemia (AML) in AML model systems, according to findings published in Cancer Disc...

The ASCO Post

July 14, 2025

Improving Use of Cytomegalovirus Negative and Irradiated Blood Products in an Outpatient Oncology Clinic

A new transfusion algorithm significantly enhances the safety of blood product transfusions for at-risk patients with hematologic malignancies.

JADPRO

July 12, 2023

Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds

Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new ...

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post

January 25, 2023

Atrium Health and Wake Forest University School of Medicine Cancer Program Appoint New Director

Atrium Health appoints Dr. Ruben A. Mesa as President and Executive Director of its cancer service line, bringing extensive expertise in hematology research and drug development to advance cancer health equity and diversity in cancer clinical trials.

The ASCO Post

March 22, 2023

The Importance of Professional Communities and Collaborations

The complexity of cancer care requires unique skill sets that must be cultivated. Collaborating with professionals specializing in different areas ensures comprehensive and patient-centered care. A mu...

JADPRO

March 22, 2023

Convergence of Hematology and Rheumatology: A Case Study

Advanced practitioners may frequently encounter patients who have a hematologic and rheumatologic diagnosis. These patients are usually managed by multiple specialists, including hematologists, rheuma...

JADPRO